<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Revvity Inc. — News on 6ix</title>
<link>https://6ix.com/company/revvity-inc</link>
<description>Latest news and press releases for Revvity Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/revvity-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835bb2d78dffbe2df116385.webp</url>
<title>Revvity Inc.</title>
<link>https://6ix.com/company/revvity-inc</link>
</image>
<item>
<title>Revvity to Hold Earnings Call on Tuesday, May 5, 2026</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026</guid>
<pubDate>Fri, 10 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 10, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2026 financial results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.</description>
</item>
<item>
<title>Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-unveils-its-signals-biodesign-offering-to-advance-biologic-research-workflows</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-unveils-its-signals-biodesign-offering-to-advance-biologic-research-workflows</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., April 09, 2026--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business is launching Signals BioDesignTM, a cloud-native molecular cloning solution that streamlines biologics research workflows. Built for biotech and pharma R&D teams, the platform simplifies complex cloning processes and enables scalable, collaborative development in a unified digital environment. It addresses the limitations of desktop tools and overly complex platforms by combining essen</description>
</item>
<item>
<title>Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-unveils-high-impact-discovery-130000749</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-unveils-high-impact-discovery-130000749</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., February 05, 2026--Revvity, Inc. (NYSE: RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation,</description>
</item>
<item>
<title>Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-announces-financial-results-fourth-110000764</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-announces-financial-results-fourth-110000764</guid>
<pubDate>Mon, 02 Feb 2026 11:00:00 GMT</pubDate>
<description>WALTHAM, Mass., February 02, 2026--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025.</description>
</item>
<item>
<title>Revvity Board Declares Quarterly Dividend</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-board-declares-quarterly-dividend-210500485</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-board-declares-quarterly-dividend-210500485</guid>
<pubDate>Mon, 26 Jan 2026 21:05:00 GMT</pubDate>
<description>WALTHAM, Mass., January 26, 2026--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026.</description>
</item>
<item>
<title>Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-hold-earnings-call-monday-211500361</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-hold-earnings-call-monday-211500361</guid>
<pubDate>Mon, 12 Jan 2026 21:15:00 GMT</pubDate>
<description>WALTHAM, Mass., January 12, 2026--Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.</description>
</item>
<item>
<title>Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-collaborates-lilly-expand-access-130000963</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-collaborates-lilly-expand-access-130000963</guid>
<pubDate>Fri, 09 Jan 2026 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.</description>
</item>
<item>
<title>Revvity to Present at J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-present-j-p-morgan-130000967</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-present-j-p-morgan-130000967</guid>
<pubDate>Thu, 18 Dec 2025 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., December 18, 2025--Revvity, Inc. (NYSE: RVTY) will present at the 44th annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 9:45 a.m. PT.</description>
</item>
<item>
<title>Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-introduces-signals-xynthetica-ai-130000475</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-introduces-signals-xynthetica-ai-130000475</guid>
<pubDate>Tue, 16 Dec 2025 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., December 16, 2025--Revvity, Inc. (NYSE: RVTY) today announced the introduction of its forthcoming Signals Xynthetica™ Models-as-a Service (MaaS) AI offering within the Revvity Signals platform. The Signals Xynthetica offering will enable AI-augmented molecular and materials design, and brings together advanced in‑silico generation, predictive modeling, and experimental validation within a single, governed environment that allows scientific teams to iteratively design, test, and r</description>
</item>
<item>
<title>VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis</title>
<link>https://6ix.com/company/revvity-inc/news/volitionrx-limited-announces-inclusion-of-its-nuqr-nets-assay-as-innovative-biomarker-in-frances-real-world-evaluation-of-early-detection-of-sepsis-1</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/volitionrx-limited-announces-inclusion-of-its-nuqr-nets-assay-as-innovative-biomarker-in-frances-real-world-evaluation-of-early-detection-of-sepsis-1</guid>
<pubDate>Thu, 04 Dec 2025 14:00:00 GMT</pubDate>
<description>VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the inclusion of its Nu.Q® NETs H3.1 assay in "DETECSEPS", a real-world evaluation of early detection of sepsis. DETECSEPS Consortium was awarded winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan, during the official ceremony held yesterday, December</description>
</item>
<item>
<title>Revvity Collaborates with MDIC and NIST to Launch New Somatic Cancer Reference Standards to Monitor Diagnostic Assay Accuracy</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-collaborates-mdic-nist-launch-130000042</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-collaborates-mdic-nist-launch-130000042</guid>
<pubDate>Mon, 10 Nov 2025 13:00:00 GMT</pubDate>
<description>WALTHAM, Mass., November 10, 2025--Revvity, Inc., today announced the launch of new highly-characterized somatic cancer reference standards developed in collaboration with the Medical Device Innovation Consortium (MDIC) and the National Institute of Standards and Technology (NIST) as part of the Somatic Reference Samples (SRS) Initiative.</description>
</item>
<item>
<title>Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-acquire-acd-labs-expand-124500458</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-acquire-acd-labs-expand-124500458</guid>
<pubDate>Mon, 10 Nov 2025 12:45:00 GMT</pubDate>
<description>WALTHAM, Mass., November 10, 2025--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acc</description>
</item>
<item>
<title>Revvity to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-present-upcoming-investor-conferences-120000077</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-present-upcoming-investor-conferences-120000077</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., October 28, 2025--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences:</description>
</item>
<item>
<title>Revvity Announces Financial Results for the Third Quarter of 2025</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-announces-financial-results-third-100000202</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-announces-financial-results-third-100000202</guid>
<pubDate>Mon, 27 Oct 2025 10:00:00 GMT</pubDate>
<description>WALTHAM, Mass., October 27, 2025--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025.</description>
</item>
<item>
<title>Revvity Showcases Progress with Purpose in 2025 Impact Report</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-showcases-progress-purpose-2025-120000555</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-showcases-progress-purpose-2025-120000555</guid>
<pubDate>Tue, 14 Oct 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., October 14, 2025--Revvity, Inc. (NYSE: RVTY) today released its annual Impact Report, a comprehensive reflection of the Company’s sustainability, social and governance strategy, initiatives and performance. This year’s report, Progress with Purpose: Science and Sustainability, highlights the Company’s strengthened partnerships, product innovation, sustainability driven investments and other efforts aimed at advancing science and human health responsibly.</description>
</item>
<item>
<title>Revvity to Hold Earnings Call on Monday, October 27, 2025</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-hold-earnings-call-monday-120000283</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-hold-earnings-call-monday-120000283</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., October 06, 2025--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2025 financial results prior to market open on Monday, October 27, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.</description>
</item>
<item>
<title>Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-announces-program-revolutionize-early-120000231</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-announces-program-revolutionize-early-120000231</guid>
<pubDate>Thu, 02 Oct 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., October 02, 2025--Revvity, Inc. (NYSE: RVTY) today announced a program for expansion of its type 1 diabetes (T1D) offering to include a population-scale assay for early detection with support from Sanofi (EURONEXT: SAN and NASDAQ: SNY). Revvity will develop a T1D 4-plex in vitro diagnostic (IVD) assay based on its existing research-use (RUO) 3-plex assay.</description>
</item>
<item>
<title>Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-unveils-ai-software-offering-120000856</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-unveils-ai-software-offering-120000856</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., September 29, 2025--Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery</description>
</item>
<item>
<title>Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-profluent-collaborate-launch-ai-120000792</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-profluent-collaborate-launch-ai-120000792</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., September 22, 2025--Revvity, Inc. (NYSE: RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity’s established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit.</description>
</item>
<item>
<title>Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina</title>
<link>https://6ix.com/company/revvity-inc/news/revvity-establishes-vivo-imaging-center-120000116</link>
<guid isPermaLink="true">https://6ix.com/company/revvity-inc/news/revvity-establishes-vivo-imaging-center-120000116</guid>
<pubDate>Tue, 02 Sep 2025 12:00:00 GMT</pubDate>
<description>WALTHAM, Mass., September 02, 2025--Revvity, Inc. (NYSE: RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state’s Research Triangle. The center consolidates Revvity’s expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies.</description>
</item>
</channel>
</rss>